Trial Profile

A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in Patients With Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EP-0057 (Primary) ; Olaparib (Primary)
Indications Bladder cancer; Brain metastases; Carcinoma; Non-small cell lung cancer; Pelvic cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

26 Feb 2025 Status changed from recruiting to active, no longer recruiting.
21 Oct 2024 Planned number of patients changed from 123 to 136.
13 Nov 2021 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com